ReviewCurrent infectious disease reports2019
The Epidemiology and Prevention of Candida auris.
Review in Current infectious disease reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Repositioning Antimicrobial Peptides Against WHO-Priority Fungi.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Consensus paper onTurkish journal of medical sciences · 2025Article
- Hospital Acquired Sepsis, Disease Prevalence, and Recent Advances in Sepsis Mitigation.Pathogens (Basel, Switzerland) · 2024Review
- Candida auris in US Correctional Facilities.Emerging infectious diseases · 2024Article
- Yeast species in the respiratory samples of COVID-19 patients; molecular tracking ofFrontiers in cellular and infection microbiology · 2024Article
- Worsening Spread ofAnnals of internal medicine · 2023Article
- First Cases ofMicroorganisms · 2022Article
- How has the COVID-19 pandemic affected gastrointestinal surgery for malignancies and surgical infections?Nagoya journal of medical science · 2021Article
- Comparative Molecular and Immunoregulatory Analysis of Extracellular Vesicles from Candida albicans and Candida auris.mSystems · 2021Article
- Frequency and co-colonization of vancomycin-resistantNew microbes and new infections · 2021Article
- Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of Candida auris Detected in a Surveillance Program.Antimicrobial agents and chemotherapy · 2021Article
- Review
- Case Report: Emergence of Candida auris in the Indian Ocean Region.The American journal of tropical medicine and hygiene · 2020Review
- Locus CauMT1 Provides a Higher-Resolution Alternative to Ribosomal Gene Sequencing for Initial Candida auris Genotyping.Journal of clinical microbiology · 2020Article
- Review
- Review
- High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis.Nature medicine · 2020Article
- Identification of Cryptic Species of FourJournal of fungi (Basel, Switzerland) · 2019Article
- Antifungal Resistance: a Concerning Trend for the Present and Future.Current infectious disease reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCandida auris has recently emerged as a pathogen with the potential for nosocomial transmission and outbreaks. The aim of this review is to summarize the global dissemination of this pathogen, characterize patient and facility characteristics associated with infection and outbreaks, and outline evidence to support interventions to prevent of transmission in the healthcare setting. RECENT
findingsC. auris has emerged separately in four clades, with international spread within a decade of its first identification and report. Acquisition and infection have predominantly been identified as healthcare-associated events. The presence of invasive devices, intensive care, and broad-spectrum antibiotic and antifungal use may be important risk factors for the development of infection due to C. auris. Nosocomial transmission is likely associated with colonization density and suboptimal infection prevention practices. The optimal strategy for reducing transmission from the environment requires further study. Candida auris is a recently emerging fungal pathogen that may cause nosocomial infections and outbreaks. Based on observed transmission patterns and interventions, key prevention measures outlined in the review include case finding and surveillance, hand hygiene, and environmental disinfection.
Indexed as
Identifiers
31044272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.